QUEST is a FREE newsletter published three times a year by the Urological Research Foundation. It informs readers of the latest advances in urologic research, especially prostate cancer treatment.
Please click here to subscribe to QUEST.
QUEST is a free newsletter, but we appreciate your support in helping the URF bring this publication to its readers.
Studying the genetics of these patients will most likely be the way to find the genes involved in developing aggressive or non- aggressive prostate cancer. Dr. Catalona* wants active surveillance patients to contact his research group for participation in a…
The study authors provided a questionnaire to oncology health care professionals in the Middle East and identified 44 herbal and 3 non-herbal nutritional supplements in use by patients with cancer. The study reviewed the herbal products to assess potential negative…
Men with baldness of any kind had a 56% higher risk of prostate cancer death compared to men with no balding. Men with moderate balding had an even higher risk of 83%. Previous studies have shown a link between baldness…
An important new study found that for men having prostate biopsies, MRI-ultrasound fusion targeted biopsies could improve detection of clinically significant prostate cancer. An MR-fusion prostate biopsy combines magnetic resonance imaging (MRI) and ultrasound imaging to target more suspicious lesions…
The proposal defined non- recommended PSA testing according to the guidelines released by the United States Preventive Services Task Force (USPSTF) in 2012. These guidelines recommend against the use of routine PSA testing in otherwise healthy men of all ages,…
The researchers’ analysis included 19 studies that pooled data on up to 118,830 patients. For overall cause of death, the adjusted hazard ratio for patients treated with radiation versus surgery was 1.63. For prostate cancer-specific death, the adjusted hazard ratio…
The TERRAIN trial included 375 patients with asymptomatic or minimally symptomatic metastatic CRPC who were randomly assigned to take enzalutamide or bicalutamide. Men in the enzalutamide group had significantly improved progression-free survival (median 15.7 months vs. 5.8 months). Xtandi (enzalutamide)…
The researchers examined the records of 37,687 men in the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Of the 3,656 men who chose to leave their cancers untreated, only 4.5% were being monitored appropriately. The study defined recommended follow-up care…
However, a new study from the University of Texas Medical Branch found no link between exposure to testosterone during a 5-year period and an increased risk of aggressive prostate cancer. The authors believe that this is the first population- based…
Researchers at Johns Hopkins assessed PHI values in 80 African- American patients with PSA values of 2-10 ng/ml prior to their radical prostatectomies. Twenty percent of the men had pathological stage 3 (pT3) prostate cancers. Although age, PSA and percentage-free…